Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.


This page shows the publications Stephen Zinner has written about Naphthyridines.
Connection Strength

  1. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn Microbiol Infect Dis. 2001 Aug; 40(4):167-71.
    View in: PubMed
    Score: 0.222
  2. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J Antimicrob Chemother. 1999 Apr; 43(4):483-90.
    View in: PubMed
    Score: 0.189
  3. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob Agents Chemother. 1998 Nov; 42(11):2841-7.
    View in: PubMed
    Score: 0.184
  4. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother. 1998 Mar; 42(3):659-65.
    View in: PubMed
    Score: 0.175
  5. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. Antimicrob Agents Chemother. 1998 Jan; 42(1):72-7.
    View in: PubMed
    Score: 0.173
  6. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul; 31(7):1054-60.
    View in: PubMed
    Score: 0.084
  7. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother. 1986 May; 29(5):927-9.
    View in: PubMed
    Score: 0.077
  8. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Sep; 20(3):201-5.
    View in: PubMed
    Score: 0.060
  9. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Jul; 20(1):44-9.
    View in: PubMed
    Score: 0.059
  10. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother. 2001 Mar; 45(3):927-31.
    View in: PubMed
    Score: 0.054
  11. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents. 2000 Dec; 16(4):407-14.
    View in: PubMed
    Score: 0.053
  12. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother. 1999 Mar; 43(3):498-502.
    View in: PubMed
    Score: 0.047
  13. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy. 2002; 48(6):275-9.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.